Zacks Investment Research Lowers Opexa Therapeutics Inc. (OPXA) to Sell

zacks-investment-research-lowers-opexa-therapeutics-inc-opxa-to-sell.jpg

Opexa Therapeutics Inc. (NASDAQ:OPXA) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Friday.
According to Zacks, “Opexa Therapeutics, Inc. develops and commercializes cell therapies to treat autoimmune diseases such as MS, rheumatoid arthritis, and diabetes. The Company is focused on autologous cellular therapy applications of its proprietary T-cell and stem cell therapies. The Company’s lead product, Tovaxin, a T-cell therapy for multiple sclerosis is in Phase IIb trials. The Company holds the exclusive worldwide license for adult multipotent stem cells derived from mononuclear cells of peripheral blood. The technology allows large quantities of monocyte derived stem cells to be produced efficiently for use in autologous therapy, thus circumventing the threat of rejection. The Company is in preclinical development for type one diabetes. “
OPXA has been the subject of a number of other reports. Chardan Capital restated a “buy” rating and issued a $6.00 price target on shares of Opexa Therapeutics in a report on Sunday, July 3rd. Maxim Group reaffirmed a “buy” rating on shares of Opexa Therapeutics in a research note on Friday, June 10th. Finally, Aegis reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Opexa Therapeutics in a research note on Monday, August 15th.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/09/zacks-investment-research-lowers-opexa-therapeutics-inc-opxa-to-sell.html

Opexa Therapeutics (NASDAQ:OPXA) opened at 4.37 on Friday. Opexa Therapeutics has a 52 week low of $1.69 and a 52 week high of $5.10. The company has a 50-day moving average of $4.22 and a 200-day moving average of $3.18. The firm’s market cap is $30.80 million.
Opexa Therapeutics (NASDAQ:OPXA) last posted its quarterly earnings results on Thursday, August 11th. The biopharmaceutical company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by $0.07. During the same period last year, the business posted ($0.56) EPS. Equities research analysts forecast that Opexa Therapeutics will post ($1.12) earnings per share for the current fiscal year.
A hedge fund recently raised its stake in Opexa Therapeutics stock. Renaissance Technologies LLC boosted its position in shares of Opexa Therapeutics Inc. (NASDAQ:OPXA) by 9.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 148,189 shares of the biopharmaceutical company’s stock after buying an additional 12,900 shares during the period. Renaissance Technologies LLC owned 2.16% of Opexa Therapeutics worth $344,000 as of its most recent SEC filing. Institutional investors and hedge funds own 6.40% of the company’s stock.
About Opexa Therapeutics
Opexa Therapeutics, Inc (Opexa) is a biopharmaceutical company. The Company is engaged in the development of a personalized immunotherapy with the potential to treat various illnesses, including multiple sclerosis (MS), as well as other autoimmune diseases, such as neuromyelitis optica (NMO). These therapies are based on its T-cell technology.

Receive News & Ratings for Opexa Therapeutics Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Opexa Therapeutics Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.

Be the first to comment on "Zacks Investment Research Lowers Opexa Therapeutics Inc. (OPXA) to Sell"

Leave a comment

Your email address will not be published.

*